Anatara Lifesciences Ltd (AU:ANR) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anatara Lifesciences is advancing its GaRP-IBS clinical trial, having reached the minimum participant requirement for Stage 2 and pausing recruitment from December 13, 2024. The trial aims to explore new treatments for Irritable Bowel Syndrome, with headline results expected in the first quarter of 2025. The company’s proactive recruitment strategy has successfully engaged participants across key sites.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.